ArticleBlood advances2021
Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning.
Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources.Blood neoplasia · 2025Trial
- Donor selection for allogeneic hematopoietic cell transplantation in the posttransplant cyclophosphamide era.International journal of hematology · 2026Review
- Don't Cut the Cord: Why Umbilical Cord Blood Still Deserves a Place in Transplantation.International journal of immunogenetics · 2026Review
- Outcome of Unrelated Umbilical Cord Blood Transplantation in India: A Less Explored Horizon.Indian pediatrics · 2025Article
- Impact of haplo-donor age on transplant outcomes: a comparative analysis of haploidentical vs cord blood transplantation.Blood advances · 2025Article
- Younger haplo-donors improve older patient survival outcomes.Blood advances · 2025Article
- Article
- Novel conditioning and prophylaxis regimens for relapse prevention.Hematology. American Society of Hematology. Education Program · 2024Review
- Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation.Transplantation and cellular therapy · 2024Article
- Review
- PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation.Blood advances · 2023Article
- Immunology of cord blood T-cells favors augmented disease response during clinical pediatric stem cell transplantation for acute leukemia.Frontiers in pediatrics · 2023Review
- In 2022, which is preferred: haploidentical or cord transplant?Hematology. American Society of Hematology. Education Program · 2022Article
- Donor T cells for CAR T cell therapy.Biomarker research · 2022Review
- Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases.Frontiers in immunology · 2022Article
- Strategies for Success With Umbilical Cord Haematopoietic Stem Cell Transplantation in Children With Malignant and Non-Malignant Disease Indications.Frontiers in cell and developmental biology · 2022Review
- Editorial: Advances in Pediatric Hematopoietic Cell Therapies and Transplantation.Frontiers in pediatrics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
Abstract
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) has emerged as an important treatment modality. Most reports comparing haplo-HSCT with posttransplant cyclophosphamide (PTCy) and other donor sources have focused on outcomes in older adults treated with reduced intensity conditioning. Therefore, in the current study, we evaluated outcomes in patients with hematological malignancy treated with myeloablative conditioning prior to haplo- (n = 375) or umbilical cord blood (UCB; n = 333) HSCT. All haplo recipients received a 4 of 8 HLA-matched graft, whereas recipients of UCB were matched at 6-8/8 (n = 145) or ≤5/8 (n = 188) HLA antigens. Recipients of 6-8/8 UCB transplants were younger (14 years vs 21 and 29 years) and more likely to have lower comorbidity scores compared with recipients of ≤5/8 UCB and haplo-HSCT (81% vs 69% and 63%, respectively). UCB recipients were more likely to have acute lymphoblastic leukemia and transplanted in second complete remission (CR), whereas haplo-HSCT recipients were more likely to have acute myeloid leukemia in the first CR. Other characteristics, including cytogenetic risk, were similar. Survival at 3 years was similar for the donor sources (66% haplo- and 61% after ≤5/8 and 58% after 6-8/8 UCB). Notably, relapse at 3 years was lower in recipients of ≤5/8 UCB (21%, P = .03) compared with haplo- (36%) and 6-8/8 UCB (30%). However, nonrelapse mortality was higher in ≤5/8 UCB (21%) compared with other groups (P < .0001). These data suggest that haplo-HSCT with PTCy after myeloablative conditioning provides an overall survival outcome comparable to that after UCB regardless HLA match group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.